Tumor immunophenotype was characterized by a strong expression of conventional myeloid antigens (CD13, CD33, CD15, MPO), although no monocytic (CD14, CD64, CD11c, CD11b, lysozyme), megakaryoblastic (CD61, CD41) and lymphoid (CD7, CD19, iCD79a, CD56, CD2) markers were found. This evidence concerns the gene FCGR1A and neoplasm.